Post-Transplant Lymphoproliferative Disorder Instructions section

Question 616: Did a new malignancy, myelodysplastic, myeloproliferative, or lymphoproliferative disease / disorder occur that is different from the disease / disorder for which the HCT or cellular therapy was performed? (Include clonal cytogenetic abnormalities, and post-transplant lymphoproliferative disorders)

Indicate whether a new or secondary malignancy, lymphoproliferative disorder, or myeloproliferative disorder was diagnosed during the reporting period. Do not report recurrence, progression, or transformation of the recipient’s primary disease (disease for which the transplant was performed) or relapse of a prior malignancy.

Report relapse of the recipient’s primary disease on the appropriate post-HCT disease-specific data form. Relapse of a prior malignancy will not be captured by the CIBMTR.

New malignancies, lymphoproliferative disorders, and myeloproliferative disorders include but are not limited to:

  • Skin cancers (basal, squamous, melanoma)
  • New leukemia
  • New myelodysplasia
  • Solid tumors
  • PTLD (post-transplant lymphoproliferative disorder) report as lymphoma or lymphoproliferative disease

The following should not be reported as new malignancy:

  • Recurrence of primary disease (report as relapse or disease progression)
  • Relapse of malignancy from recipient’s pre-HCT medical history
  • Breast cancer found in other (i.e., opposite) breast (report as relapse)
  • Post-HCT cytogenetic abnormalities associated with the pre-HCT diagnosis (report as relapse)
  • Transformation of MDS to AML post-HCT (report as disease progression)

If a new malignancy, lymphoproliferative disorder, or myeloproliferative disorder was diagnosed during the reporting period, report “yes” and completed questions 617-639. If no new malignancies or disorders were diagnosed during the reporting period, report “no” and continue with question 640.

Copy and complete questions 617-639 to report each new malignancy diagnosed since the date of last report. The submission of a pathology report or other supportive documentation for each reported new malignancy is strongly recommended.

Questions 617-619: Specify the new malignancy:

Indicate which new malignancy / disorder was diagnosed during the reporting period and indicate the date of diagnosis in question 619. Report the pathologic diagnosis date. If the original assessment confirming diagnosis is not available, report the date of diagnosis indicated in the progress notes.

For more information regarding reporting partial or unknown dates, see General Instructions, General Guidelines for Completing Forms.

Question 620-621: Was the new malignancy donor / cell product derived?

Indicate whether the new malignancy originated from the donor / cell product. If “yes,” indicate whether documentation was submitted to CIBMTR (e.g., cell origin evaluation (VNTR, cytogenetics, FISH)) in question 621.

For further instructions on how to attach documents in FormsNet3, refer to the training guide.

Question 622: Was documentation submitted to the CIBMTR? (e.g., pathology report, autopsy report)

Indicate whether documentation of the new malignancy, lymphoproliferative disorder, or myeloproliferative disorder was submitted to CIBMTR (e.g., pathology report, autopsy report).

For further instructions on how to attach documents in FormsNet3, refer to the training guide.

Post-Transplant Lymphoproliferative Disorder

Question 623: Was there EBV reactivation in the blood?

If reactivation in the blood was confirmed during the reporting period, report “yes” and continue with question 624. If reactivation did not occur during the reporting period report “no” and continue with question 629.

Indicate “unknown” if no EBV testing was performed during the reporting period.

Question 625-628: How was EBV reactivation diagnosed?

Indicate the method of detection for EBV reactivation.

If reactivation was diagnosed by “qualitative PCR of blood,” continue with question 629.

If the diagnoses was made by “quantitative PCR of blood,” report the number of copies detected in question 626. Also, indicate whether repeat testing was performed during the reporting period in question 627. If repeat testing was performed, report the results of the most recent test performed during the reporting period in question 628.

If the diagnosis was made by “Other method,” specify the method of detection in question 625 and then continue with question 630.

Question 627: Quantitative EBV viral load of blood (at diagnosis of EBV)

If EBV reactivation was diagnosed by quantitative PCR of blood, report the EBV viral blood load at diagnosis.

Question 629: Was there lymphomatous involvement? (e.g., a mass)

Indicate whether a mass or other lymphomatous involvement was detected during the reporting period. If there was lymphomatous involvement was confirmed during the reporting period, report “yes” and complete questions 630-637. If lymphomatous involvement was not confirmed during the reporting period, report “no” and continue with question 638.

Question 630-637: Specify sites of PTLD involvement:

For each site listed, indicate whether there was post-transplant lymphoproliferative disorder (PTLD) involvement. Sites may be identified by radiographic or pathologic methods. If there was PTLD involvement at a site not listed, report “other site” and specify in question 637.

Question 638-639: Was PTLD confirmed by biopsy?

Indicate whether PTLD was confirmed by a biopsy. If PTLD was confirmed by a biopsy, report “yes” and indicate whether documentation was submitted to CIBMTR (e.g., pathology report) in question 639. If a biopsy did not confirm the diagnosis of PTLD, report “no” and continue with question 640.

For further instructions on how to attach documents in FormsNet3, refer to the training guide.

Last modified: Jan 31, 2017

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.